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Abstract
Background: Malaria is the infectious disease causing the highest morbidity and mortality in
Angola and due to widespread chloroquine (CQ) resistance, the country has recently changed its
first-line treatment recommendations for uncomplicated malaria, from CQ to artemisinin
combination therapies (ACT) in adults, and sulphadoxine/pyrimethamine (S/P) in pregnant women.
Loss of SP sensitivity is, however, progressing rapidly in Africa and, in this study, were investigated
a number of molecular markers associated to CQ and S/P.
Methods: Blood samples were collected from 245 children with uncomplicated malaria, admitted
at the Pediatric Hospital Dr. David Bernardino (HPDB), Angola, and the occurrence of mutations
in Plasmodium falciparum was investigated in the pfmdr1 (N86Y) and pfcrt (K76T) genes, associated
with CQ resistance, as well as in pfdhfr (C59R) and pfdhps (K540E), conferring SP resistance.
Results: The frequencies of pfmdr1 mutations in codon 86 were 28.6% N, 61.3% Y and 10.1%
mixed infections (NY). The frequency of pfcrt mutations in codon 76 were 93.9% K, 5.7% T and
0.4% mixed infections (KT). For pfdhfr the results were in codon 59, 60.6% C, 20.6% R and 18.8%
mixed infections (CR). Concerning pfdhps, 6.3% of the isolates were bearers of the mutation 540E
and 5.4% mixed infections (K540E).
Conclusion: The results of this epidemiologic study showed high presence of CQ resistance
markers while for SP a much lower prevalence was detected for the markers under study.
Background
Malaria is endemic throughout much of the Angolan ter-
ritory, and is by far the highest cause of morbidity and
mortality particularly among children under five years old
and pregnant women. Malaria continues to be responsi-
ble for 50% of all outpatient attendance and around 25%
of all hospital deaths http://www.rollbackmalaria.org/
wmr2005/. Recently and according to the Angola Malaria
Indicator Survey, 2007, http://www.procaare.org/archive/
procaare/200804 these figures have been reduced due to
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control programmes, but about 35% of all cases and 70%
of all deaths reported annually occur in children under
five years of age.
The first cases of resistance to chloroquine (CQ) were
described in the eighties [1-4]. As a consequence of
increasing rates of clinical resistance to CQ, the proto-
col at the Pediatric Hospital David Bernardino
(HPDB) was changed, in 2006, two combined thera-
pies artesunate with lumefantrine (Coartem®), and
amodiaquine (AQ) with sulphadoxine-pyrimeth-
amine (SP – Fansidar®) as first-line treatments of
uncomplicated malaria.
The  pfmdr1  gene (multidrug resistance) has been
described as associated with CQ resistance [5-7], with a
polymorphism resulting from the substitution of an
asparagine for a tyrosine in amino acid 86 (N86Y) in Plas-
modium falciparum [8-14]. CQ resistance is also associated
with a mutation in the transporter gene pfcrt where the
amino acid substitution at pfcrt codon 76 (K to T) has
been shown to have a determinant association with the
resistance phenotype [15-19].
Plasmodium falciparum resistance to sulphadoxine and
pyrimethamine (SP) is conferred by mutations of the
dihydropteroate synthase (pfdhps) and dihydrofolate
reductase (pfdhfr) genes, respectively [20-23]. pfdhfr 108N
mutation seems to be enough to confer resistance to
pyrimethamine [24,25]. The presence of a mutation at
positions 51 (N51I) or 59 (C59R), together with S108N
confer a considerable increase in the resistance level to
pyrimethamine when compared with mutation S108N by
itself [26-28].
Mutations in codons 437 (A437G) and 540 (K540E) of P.
falciparum pfdhps are associated with resistance to sul-
phadoxine. The quintuple mutant (triple pfdhfr: 51I, 59R,
108N and double pfdhps: 437G, 540E) is considered as the
molecular marker of SP treatment failure [29-34]. Studies
of genetic transfection of P. falciparum, confirmed that the
amino acid substitution at pfdhfr  codon 108 (S→N),
increases approximately ten times the resistance to
pyrimethamine [35]. Epidemiology studies also demon-
strated that the presence of mutations 59R in pfdhfr and
540E in pfdhps are significantly associated to resistance as
well as to the presence of the other above mentioned
mutations [30,36,37].
In this work were investigated the frequencies of muta-
tions associated with chloroquine resistance (pfmdr1
N86Y and pfcrt K76T) and also screened for the two muta-
tions associated to the resistance of P. falciparum to SP as
used in populations from high malaria transmission
areas.
Materials and methods
Sample collection
Blood samples included in this study were collected from
children between 1 and 16 years, at the HPDB Hospital in
Luanda, Angola, and individually spotted on Whatman
n.°4 filter paper, after microscopic confirmation of P. fal-
ciparum  infection. Parent's informed consent was
obtained before inclusion of the blood samples in the
study which was reviewed and approved by the Ethical
Committees from the Ministry of Health of Angola and of
the HPDB. Original study was associated to quinine treat-
ment and published elsewhere [38].
Genetic characterization of the parasites
Parasite DNA was extracted from dried blood spots, using
Chelex as described elsewhere [39]. P. falciparum muta-
tions associated with resistance to CQ and SP were typed
by PCR-RFLP as described elsewhere [39,40], primers
sequences, amplification cycles and restrictions enzymes
are described in table 1 and 2, respectively. In this study,
the following codons and polymorphisms were analysed:
pfmdr1 86, pfcrt 76; pfdhfr 59 and pfdhps 540. Amplicons
and fragments were separated on 2% or 3% agarose gels
stained with ethidium bromide and visualized under UV.
Statistical analysis
Associations between the different mutations were tested
by Fisher's exact test.
Results
Patients and parasites
From the 245 isolates of P. falciparum parasites used in
this study, 199 samples were successfully typed by PCR-
RFLP for pfmdr1, for pfcrt 245, for pfdhps 221 and for pfdhfr
224. Mutant alleles were detected in four loci: pfcrt 76T,
pfmdr1 86Y, pfdhps 540E and pfdhfr 59R Figure 1.
pfmdr1 and pfcrt
As shown in Table 3, the frequency of the pure mutant
allele  pfcrt  T76 was 93.9%. Only one isolate carried a
mixed population KT for this allele (0.41%). The fre-
quency of the mutant pfmdr1 Y86 allele was 61.3% and
mixed pfmdr1 N and Y allele was detected in 10.1% of the
isolates.
To study the associations between the loci pfcrt K76T and
pfmdr1 N86Y, 176 single infection isolates were analysed.
Among the 165 isolates with the pfcrt T76 mutation, 115
(70%) also carried the mutant pfmdr1 Y86 allele. Whether
or not the mixed infections were excluded from the anal-
ysis, the association between the two mutant alleles was
significant (P = 0.029, mixed infections excluded).
pfdhps and pfdhfr
One locus of pfdhps (K540E) and one of pfdhfr (C59R)
were investigated (Table 3). For the pfdhps 88.3% of theMalaria Journal 2008, 7:236 http://www.malariajournal.com/content/7/1/236
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isolates carried the mutant allele E540 and 5.4% carried
mixed (K and E) alleles. For pfdhfr 60.6% were wild type
(C59) and 18.8% were mixed populations. To study the
associations between the pfdhps E540 and pfdhfr R59 loci,
only 61 single infection isolates were analysed, and there
was no association between pfdhps E540 and pfdhfr R59 (P
= 0.159).
Discussion
In vivo resistance to CQ and SP have reached high levels in
some regions of Angola, where resistance to these drugs is
high (25%) [41]. This study reveals a high frequency of
drug resistance molecular markers for, CQ (pfcrt  T76;
93.9% and pfmdr1 Y86; 61.3%) and SP (9% of bearers
with quintuple mutant).
Agarose gels showing pfmdr1 86, pfcrt 76, pfdhfr 59 and pfdhps 540 PCR-RFLP products of control and field-collected samples  of P. falciparum Figure 1
Agarose gels showing pfmdr1 86, pfcrt 76, pfdhfr 59 and pfdhps 540 PCR-RFLP products of control and field-col-
lected samples of P. falciparum. pfmdr1: 2-N86; 3-Y86; 4-N/Y86; 5-3D7 (N86); 6-Dd2 (Y86). pfcrt: 2-k76; 3-T76; 4-K/T76; 
5-K1 (K76); 6-3D7 (T76). pfdhfr: 2-C59; 3-R59; 4-R/C59; 5-N3 (C59); 6-T9/94 (R59). pfdhps: 2-E540; 3-K540; 4-K/E540; 5-HB3 
(E540); 6-K1 (K540). In all gels lanes 1 and 7 shows the molecular weight marker.
321bps
249bps
72bps
500bps 500bps
261bps
137bps
124bps
500bps
189bps
162bps
137bps
500bps
439bps
354bps
85bps
1234567 123 4 5 6 7
1234567 123456 7Malaria Journal 2008, 7:236 http://www.malariajournal.com/content/7/1/236
Page 4 of 7
(page number not for citation purposes)
In this study, associations within and between the muta-
tions that confer resistance against CQ and those consid-
ered predictive of SP treatment failure were evaluated.
Obtained data revealed an association (P  = 0.029)
between pfcrt T76 (chromosome 7) and pfmdr1 Y86 (chro-
mosome 5) as reported by other authors [42-45].
Presence of mutations R59 and E540 in pfdhfr and pfdhps,
respectively, is considered a marker of confirmed resist-
ance to SP and our data indicates that 9% of the children
attending the HPDB, were bearers of P. falciparum para-
sites with the SP quintuple mutant associated usually to
treatment failure. These results are in line with others
from western Africa, where low prevalence of the quintu-
ple mutant has been observed [46,47]. Although the pre-
dictive value of these markers for SP treatment failure has
not been established in this study, these results emphasize
the need for close monitoring of mutation prevalence
with treatment outcome, since these antimalarials are
now used as first line treatment of uncomplicated malaria
in children attending the HPDB as well as prophylactic
treatment in pregnant women.
Inter- and intragenic association of pfdhfr  and  pfdhps
mutant codons was indirectly proven in other studies
where SP resistance was found to be associated with dou-
ble up to quintuple mutations in both genes [48,49].
Here, only 9% of the samples, with concurrence of the pfd-
hfr  and  pfdhps  variants, R59 and E450 simultaneously
were observed, which are considered to be predictive of
the quintuple mutant (pfdhfr  I51, R59, N108, pfdhps
Table 1: PCR Programme for the genes pfmdr1 86, pfcrt 76, pfdhps 540, pfdhfr 59, primer and product size
Gene Primers PCR Programme Product size (bp)
Pfmdr1 86 754N 754R Initial step 92°C 3 min 321
Denaturation (35×) 92°C 1 min
Annealing (35×) 51°C 30 s
Extension (35×) 72°C 1 min
Final step 72°C 3 min
Pfcrt 76 1° nested 76o1F N1R Initial step 94°C 3 min 528
Denaturation (40×) 94°C 45 s
Annealing (40×) 55°C 45 s
Extension (40×) 72°C 45 s
Final step 72°C 3 min
Pfcrt 76 2° nested 76 N2F 76 N2R Initial step 94°C 3 min 271
Denaturation (35×) 94°C 45 s
Annealing (35×) 53°C 45 s
Extension (35×) 72°C 45 s
Final step 72°C 3 min
Pfdhps 540 540 F 540 R Initial step 94°C 3 min 439
Denaturation (40×) 94°C 1 min
Annealing (40×) 45°C 1 min
Extension (40×) 72°C 1 min
Final step 72°C 3 min
Pfdhfr 59 59 F 59 R Initial step 94°C 3 min 326
Denaturation (35×) 94°C 1 min
Annealing (35×) 55°C 1 min
Extension (35×) 72°C 1 min
Final step 72°C 3 min
Table 2: Fragments length, clones and enzymes used for 
digestion of the codons 86 Pfmdr 1, 76 Pfcrt, 540 Pfdhps and 59 
Pfdhfr.
Gene Enzyme clone Codon Fragments length
Pfmdr1 86 ApoI 3D7 AAT (Asn) 249 + 72 bp
Dd2 TAT (Tyr) 321 bp
Pfcrt 76 ApoI 3D7 AAA (Lys) 137 + 124 + 10 bp
K1 ACA (Thr) 261 + 10 bp
Pfdhps 540 BseGI N3 GAA (Glu) 354 + 85 bp
T9/94 AAA (Lys) 439 bp
Pfdhfr 59 PdmI K1 CGT (Arg) 354 + 85 bp
HB3 TGT (Cys) 439 bp
Table 3: Prevalence of mutations conferring resistance to 
chloroquine and sulphadoxine/pyrimethamine in Plasmodium 
falciparum isolates from Angola
Gene Mutation n Mutation (%) Mixed* (%)
Pfcrt T76 245 93.9 (230/245) 0.4 (1/245)
pfmdr1 Y86 199 61.3 (122/199) 10.1 (20/199)
pfdhfr R59 224 20.6 (46/224) 18.8 (42/224)
pfdhps E540 221 6.3 (14/221) 5.4 (12/221)
*refers to mixed populations of P. falciparum parasites.Malaria Journal 2008, 7:236 http://www.malariajournal.com/content/7/1/236
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G437, E540) associated to SP treatment failure [37,50-
53]. All other samples had presence of one or the other
mutation suggesting that fixation of the quintuple mutant
was still an on going process.
Association between mutations on pfcrt,  pfmdr1,  pfdhfr
and pfdhps, have been reported from West Africa [54,55]
but reports on linkage between response to treatment
with CQ and SP, in the same patients, is rare. Even though
no statistic association was found, 43 double mutants for
pfdhfr/pfcrt, 21 for pfdhfr/pfmdr1, 12 pfdhps/pfcrt  and 6
pfdhps/pfmdr1  were detected. Regarding the association
between mutations conferring resistance to SP and CQ;
almost all of the isolates carrying the mutant genotype for
pfdhfr (43 out of 46) or pfdhps (12 out of 14) carried at
least one of the CQ associated mutations in the genes pfcrt
or pfmdr1. This reflects the possible association and accu-
mulation of at least three or four out of 7 mutations (pfcrt
T76, pfmdr1 Y86, pfdhfr: N108, I51, R59 and pfdhps: G437,
E540) scattered on four different chromosomes and
involved in resistance to three different antimalarials,
chloroquine, sulfadoxine and pyrimethamine.
As a result of this study it is not possible to comment
whether the presence of pfcrt T76 favors the presence of
pfdhfr and pfdhps mutations or vice versa because this
requires longitudinal and long lasting studies and obser-
vations. Despite these difficulties in drawing firm conclu-
sions, several previous findings support the hypothesis of
linkage disequilibrium between mutations associated
with SP resistance and CQ resistance. In a murine malaria
model, CQ resistance could be induced in pyrimeth-
amine-resistant parasites, but not in sensitive ones [56].
In field isolates, several observations indicate that it is
more likely to find mutations in pfdhfr and pfdhps in iso-
lates exhibiting already pfcrt T76 mutation than in isolates
comprising pfcrt wild type parasites [57-59]. The reason
for this apparent association between resistance to CQ
and SP is obscure since both drugs have distinct modes of
action and resistance to these is determined by mutations
on different chromosomes [60-62]. The accelerated acqui-
sition of resistance to multiple drugs (ARMD) possibly
reflecting a rapid mutator phenotype [63] could be one
explanation.
Multiple CQ and SP resistance mutations are thought to
have higher fitness cost of the parasite asexual reproduc-
tion (reviewed in [64,65]). In line with the previous con-
siderations, the reproductive capacity of mutant strains is
believed to be jeopardized [64-66]. The results did not
reflect these since gametocyte prevalence in infections
with mutant-type parasites, was not higher than in infec-
tions with wild-type isolates.
Conclusion
This was the first molecular study carried out in this geo-
graphical area including a considerable number of sam-
ples (245) and focused in the mutations of pfmdr1, pfcrt,
pfdhps and pfdhfr genes, strongly associated to CQ and SP
resistance. The results of the epidemiological study on
prevalence of genotypes associated with drug resistance,
carried out at a HPDB in Luanda, showed high presence of
CQ resistance markers, while for SP a much lower preva-
lence was detected. This work can be important to evalu-
ate the implementation of new therapeutics strategies
based on combinations that includes SP, like the protocol
that are now implemented in HPDB (artesunate com-
bined with SP) as first-line drug for uncomplicated
malaria treatment.
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